Keep climbing.

HER2CLIMB demonstrated the addition of the HER2-TKI tucatinib to trastuzumab and capecitabine has significant intracranial activity for women with HER2+ brain mets. Here we have longer follow-up on the 291 women with brain mets reporting quite the improvement in overall survival from 13 to 22 months. The risk of developing new brain mets was also roughly halved (HR 0.55). The combo of tucatinib to trastuzumab and capecitabine is an important option, particularly for those with repetitive intracranial progression. | Lin, JAMA Oncol 2022